stockrow
Friday 6 November 2026
Export KYMR’s income statement to Excel — free account
Kymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
131.25
3.13
+2.44%
Follow KYMR
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 3 | 3 | 2 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z-Score |
23.22 | 11.35 | 3.50 | 6.15 | 12.25 | 3.03 | — | — | — |
P/S ratio |
167.66 | 64.14 | 18.83 | 28.61 | 41.83 | 31.61 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
9.79 | 4.82 | 1.00 | 4.47 | 4.84 | 2.55 | (0.85) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.61 | 0.00 | — | — |
Beneish M-Score |
— | — | (0.05) | 23.26 | (2.13) | — | — | — | — |
P/Operating CF |
(98.49) | (48.86) | 183.91 | (33.89) | (79.44) | (53.60) | (5.84) | — | — |
P/B ratio |
4.16 | 3.61 | 3.75 | 2.73 | 6.63 | 3.79 | 0.00 | — | — |
Price to Tangible BV |
4.16 | 3.61 | 3.75 | 2.73 | 6.63 | 3.79 | 0.00 | — | — |
EV/Sales |
146.07 | 53.80 | 14.07 | 19.94 | 35.77 | 22.92 | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
(24.59) | (13.02) | (10.76) | (6.10) | (20.21) | 8.85 | 4.34 | — | — |
EV/FCF |
(24.44) | (12.21) | (8.05) | (5.99) | (19.96) | 9.87 | 2.13 | — | — |
Quick Ratio |
10.19 | 7.21 | 4.55 | 5.74 | 4.78 | 2.68 | 2.66 | 8.83 | — |
Current Ratio |
10.47 | 7.53 | 4.73 | 5.88 | 4.88 | 2.73 | 2.69 | 8.92 | — |
Net Debt/EBITDA |
2.42 | 1.81 | 2.23 | 2.58 | 4.78 | 6.88 | 2.19 | 1.91 | — |
Debt/Assets |
0.08% | 0.23% | 0.23% | 0.21% | 0.19% | 0.12% | 1.00% | 1.57% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | — |
Asset Turnover |
0.03 | 0.06 | 0.13 | 0.08 | 0.13 | 0.11 | 0.04 | 0.00 | — |
Operating CF/Net income |
0.75 | 0.87 | 0.70 | 0.99 | 1.29 | (1.61) | (0.43) | 0.83 | — |
Capex/Depreciation |
2.56 | 1.94 | 20.72 | (0.73) | (0.19) | (2.73) | (0.64) | 0.00 | — |
Interest Coverage |
(944.32) | (1,050.74) | (844.54) | (916.23) | (574.46) | (402.64) | (917.50) | (2,681.37) | — |
| (25.78%) | (36.38%) | (33.21%) | (32.60%) | (26.96%) | (52.17%) | 75.79% | 39.45% | — | |
| (22.89%) | (28.81%) | (24.93%) | (25.61%) | (18.34%) | (18.10%) | (51.26%) | (97.07%) | — | |
ROIC |
(29.80%) | (46.84%) | (483.64%) | (119.65%) | (342.22%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(37.46%) | (45.41%) | (39.96%) | (42.83%) | (27.04%) | (26.98%) | (66.45%) | (54.56%) | — |
Average Days of Receivables |
0.00 | 0.00 | 69.66 | 19.78 | 0.68 | 6.19 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
807.34% | 510.38% | 240.59% | 350.76% | 188.13% | 182.48% | 1,266.46% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
173.90% | 134.97% | 70.03% | 93.61% | 49.90% | 53.57% | 272.02% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
152.77% | 116.87% | 54.86% | 75.77% | 34.29% | 15.25% | 40.76% | — | — |
Graham Net Nets |
0.11 | 0.12 | 0.15 | 0.23 | 0.10 | 0.09 | 1.39 | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
(4.73%) | (7.38%) | (9.94%) | (11.59%) | (3.24%) | (21.39%) | (0.78%) | — | — |
Free Cash Flow Yield |
(3.56%) | (6.87%) | (9.28%) | (11.64%) | (4.28%) | 7.35% | (17.03%) | — | — |
Revenue per Share |
0.46 | 0.63 | 1.35 | 0.87 | 1.52 | 1.96 | 1.73 | 0.00 | — |
Operating CF per Share |
(2.76) | (2.59) | (1.76) | (2.84) | (2.69) | 5.08 | 10.54 | (0.40) | — |
Capex per Share |
(0.02) | (0.17) | (0.59) | (0.05) | (0.03) | (0.52) | (0.31) | 0.00 | — |
Free Cash Flow per Share |
(2.77) | (2.76) | (2.35) | (2.89) | (2.72) | 4.56 | 10.23 | (0.40) | — |
Cash per Share |
10.04 | 6.51 | 6.42 | 7.55 | 9.22 | 17.07 | 54.12 | 0.93 | — |
Shareholders Equity per Share |
18.70 | 11.14 | 6.77 | 9.09 | 9.58 | 16.36 | 20.41 | 0.88 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
18.70 | 11.14 | 6.77 | 9.09 | 9.58 | 16.36 | 20.41 | 0.88 | — |
Free Cash Flow |
(234.34) | (207.34) | (137.31) | (155.92) | (130.54) | 79.03 | 17.37 | (17.86) | — |
Working Capital |
788.00 | 442.50 | 319.63 | 348.07 | 358.73 | 191.72 | 58.28 | 37.10 | — |
Capital Expenditures |
(1.45) | (12.84) | (34.48) | (2.84) | (1.60) | (9.10) | (0.53) | (1.36) | — |
Net Current Asset Value |
708.07 | 367.85 | 224.53 | 306.43 | 305.01 | 99.05 | 10.82 | 36.55 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.04 | 0.27 | 0.44 | 0.06 | 0.02 | 0.27 | 0.18 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
(0.01) | (0.13) | (0.03) | 0.29 | 0.69 | 0.31 | 0.22 | 0.09 | — |
Cash ROIC |
(9.65%) | (15.63%) | (17.81%) | (17.35%) | (14.45%) | 13.61% | 13.59% | (22.07%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 8.96 | 35.05 | 204.58 | 93.89 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,660.68 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | — |
Average Receivables |
— | — | 8.77 | 1.34 | 0.36 | 0.36 | — | 0.79 | — |
Average Payables |
5.00 | 6.53 | 5.71 | 4.17 | 4.19 | 3.82 | 2.67 | 2.67 | — |
Average Assets |
1,360.42 | 776.90 | 589.45 | 604.52 | 546.54 | 301.94 | 80.47 | 22.12 | — |
Average Common Equity |
1,207.64 | 615.29 | 442.56 | 474.89 | 371.76 | 104.74 | (54.42) | (54.42) | — |
Columns are period end dates · fundamentals updated 2 Nov 2026